| Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region KP Lesch, D Bengel, A Heils, SZ Sabol, BD Greenberg, S Petri, ... Science 274 (5292), 1527-1531, 1996 | 6028 | 1996 |
| Allelic variation of human serotonin transporter gene expression A Heils, A Teufel, S Petri, G Stöber, P Riederer, D Bengel, KP Lesch Journal of neurochemistry 66 (6), 2621-2624, 1996 | 2590 | 1996 |
| EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)–revised report of an EFNS task force EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: European journal of neurology 19 (3), 360-375, 2012 | 671 | 2012 |
| Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis W Van Rheenen, A Shatunov, AM Dekker, RL McLaughlin, FP Diekstra, ... Nature genetics 48 (9), 1043-1048, 2016 | 330 | 2016 |
| Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene A Heils, A Teufel, S Petri, M Seemann, D Bengel, U Balling, P Riederer, ... Journal of Neural Transmission/General Section JNT 102 (3), 247-254, 1995 | 309 | 1995 |
| Guidelines for preclinical animal research in ALS/MND: A consensus meeting AC Ludolph, C Bendotti, E Blaugrund, A Chio, L Greensmith, JP Loeffler, ... Amyotrophic Lateral Sclerosis 11 (1-2), 38-45, 2010 | 274 | 2010 |
| Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn‐superoxide dismutase mutant mice M Damiano, AA Starkov, S Petri, K Kipiani, M Kiaei, M Mattiazzi, ... Journal of neurochemistry 96 (5), 1349-1361, 2006 | 264 | 2006 |
| Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB–mediated pathogenic pathways V Swarup, D Phaneuf, N Dupré, S Petri, M Strong, J Kriz, JP Julien Journal of Experimental Medicine 208 (12), 2429-2447, 2011 | 245 | 2011 |
| ALSFRS-R score and its ratio: a useful predictor for ALS-progression K Kollewe, U Mauss, K Krampfl, S Petri, R Dengler, B Mohammadi Journal of the neurological sciences 275 (1-2), 69-73, 2008 | 209 | 2008 |
| High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study M Graf, D Ecker, R Horowski, B Kramer, P Riederer, M Gerlach, C Hager, ... Journal of neural transmission 112 (5), 649-660, 2005 | 197 | 2005 |
| Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis M Kiaei, K Kipiani, S Petri, J Chen, NY Calingasan, MF Beal Neurodegenerative Diseases 2 (5), 246-254, 2005 | 195 | 2005 |
| Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis M Kiaei, S Petri, K Kipiani, G Gardian, DK Choi, J Chen, NY Calingasan, ... Journal of Neuroscience 26 (9), 2467-2473, 2006 | 188 | 2006 |
| Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis S Petri, M Kiaei, K Kipiani, J Chen, NY Calingasan, JP Crow, MF Beal Neurobiology of disease 22 (1), 40-49, 2006 | 176 | 2006 |
| Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis A Neymotin, NY Calingasan, E Wille, N Naseri, S Petri, M Damiano, ... Free Radical Biology and Medicine 51 (1), 88-96, 2011 | 169 | 2011 |
| Cell‐permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis S Petri, M Kiaei, M Damiano, A Hiller, E Wille, G Manfredi, NY Calingasan, ... Journal of neurochemistry 98 (4), 1141-1148, 2006 | 160 | 2006 |
| Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model HJ Westeneng, TPA Debray, AE Visser, RPA van Eijk, JPK Rooney, ... The Lancet Neurology 17 (5), 423-433, 2018 | 152 | 2018 |
| HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients W Guo, M Naujock, L Fumagalli, T Vandoorne, P Baatsen, R Boon, ... Nature communications 8 (1), 1-15, 2017 | 137 | 2017 |
| Nrf2/ARE signaling pathway: key mediator in oxidative stress and potential therapeutic target in ALS S Petri, S Körner, M Kiaei Neurology research international 2012, 2012 | 137 | 2012 |
| Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis A Sarlette, K Krampfl, C Grothe, N Neuhoff, R Dengler, S Petri Journal of Neuropathology & Experimental Neurology 67 (11), 1055-1062, 2008 | 123 | 2008 |
| Impaired DNA damage response signaling by FUS-NLS mutations leads to neurodegeneration and FUS aggregate formation M Naumann, A Pal, A Goswami, X Lojewski, J Japtok, A Vehlow, ... Nature communications 9 (1), 1-17, 2018 | 108 | 2018 |
